Literature DB >> 22851267

Re: CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the Breast International Group 1-98 trial.

Vincent Stanton.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22851267     DOI： 10.1093/jnci/djs305

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN： 0027-8874            Impact factor:   13.506


× No keyword cloud information.
  15 in total

1.  Tamoxifen use in postmenopausal breast cancer: CYP2D6 matters.

Authors:  Hiltrud Brauch; Werner Schroth; Matthew P Goetz; Thomas E Mürdter; Stefan Winter; James N Ingle; Matthias Schwab; Michel Eichelbaum
Journal:  J Clin Oncol       Date:  2012-10-22       Impact factor: 44.544

2.  Re: Concordance between CYP2D6 genotypes obtained from tumor-derived and germline DNA.

Authors:  Matthew P Goetz; Hiltrud Brauch; Mark J Ratain; Nancy J Cox; Yusuke Nakamura; Richard Weinshilboum; James N Ingle
Journal:  J Natl Cancer Inst       Date:  2014-04-03       Impact factor: 13.506

Review 3.  Cytochrome P-450 2D6 (CYP2D6) Genotype and Breast Cancer Recurrence in Tamoxifen-Treated Patients: Evaluating the Importance of Loss of Heterozygosity.

Authors:  Thomas P Ahern; Daniel L Hertz; Per Damkier; Bent Ejlertsen; Stephen J Hamilton-Dutoit; James M Rae; Meredith M Regan; Alastair M Thompson; Timothy L Lash; Deirdre P Cronin-Fenton
Journal:  Am J Epidemiol       Date:  2016-12-17       Impact factor: 4.897

4.  Trends in co-prescribing of antidepressants and tamoxifen among women with breast cancer, 2004-2010.

Authors:  Stacie B Dusetzina; G Caleb Alexander; Rachel A Freedman; Haiden A Huskamp; Nancy L Keating
Journal:  Breast Cancer Res Treat       Date:  2012-11-13       Impact factor: 4.872

5.  Concordance between CYP2D6 genotypes obtained from tumor-derived and germline DNA.

Authors:  James M Rae; Meredith M Regan; Jacklyn N Thibert; Christina Gersch; Dafydd Thomas; Brian Leyland-Jones; Giuseppe Viale; Lajos Pusztai; Daniel F Hayes; Todd Skaar; Catherine Van Poznak
Journal:  J Natl Cancer Inst       Date:  2013-08-19       Impact factor: 13.506

Review 6.  Metabolism and transport of tamoxifen in relation to its effectiveness: new perspectives on an ongoing controversy.

Authors:  Deirdre P Cronin-Fenton; Per Damkier; Timothy L Lash
Journal:  Future Oncol       Date:  2014-01       Impact factor: 3.404

7.  Loss of heterozygosity at the CYP2D6 locus in breast cancer: implications for germline pharmacogenetic studies.

Authors:  Matthew P Goetz; James X Sun; Vera J Suman; Grace O Silva; Charles M Perou; Yusuke Nakamura; Nancy J Cox; Philip J Stephens; Vincent A Miller; Jeffrey S Ross; David Chen; Stephanie L Safgren; Mary J Kuffel; Matthew M Ames; Krishna R Kalari; Henry L Gomez; Ana M Gonzalez-Angulo; Octavio Burgues; Hiltrud B Brauch; James N Ingle; Mark J Ratain; Roman Yelensky
Journal:  J Natl Cancer Inst       Date:  2014-12-08       Impact factor: 13.506

Review 8.  PharmGKB summary: tamoxifen pathway, pharmacokinetics.

Authors:  Daniel J Klein; Caroline F Thorn; Zeruesenay Desta; David A Flockhart; Russ B Altman; Teri E Klein
Journal:  Pharmacogenet Genomics       Date:  2013-11       Impact factor: 2.089

Review 9.  Pharmacogenomics of breast cancer therapy: an update.

Authors:  Kelly Westbrook; Vered Stearns
Journal:  Pharmacol Ther       Date:  2013-03-13       Impact factor: 12.310

10.  Variants in tamoxifen metabolizing genes: a case-control study of contralateral breast cancer risk in the WECARE study.

Authors:  Jennifer D Brooks; Sharon N Teraoka; Kathleen E Malone; Robert W Haile; Leslie Bernstein; Charles F Lynch; Lene Mellemkjær; David J Duggan; Anne S Reiner; Patrick Concannon; Katherine Schiermeyer; Juan Pablo Lewinger; Jonine L Bernstein; Jane C Figueiredo
Journal:  Int J Mol Epidemiol Genet       Date:  2013-03-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.